跳至主要内容
临床试验/NCT03880136
NCT03880136已完成1 期

A Phase 1 Single Center, Open-Label, Randomized Two-Period, Two-Arm Crossover Study of the Relative Bioavailability of a Single Dose of CTP-543 in Fasted and Fed Conditions in Healthy Volunteers

Concert Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2019年3月25日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
14
试验地点
1
主要终点
Measurement of CTP-543 in plasma under fed and fasted conditions

研究概览

简要总结

Two period crossover study to assess the bioavailability of CTP-543 under fed and fasted conditions.

详细描述

This open-label, single-dose study will assess in healthy subjects a solid oral dose formulation of CTP-543 under fasted and fed conditions.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy adults between 18 and 55 years of age, inclusive
  • Body weight not less than 100 lbs and body mass index within the range of 18 to 32 kg/m2, inclusive, at screening

排除标准

  • History of clinically significant central nervous system (e.g., seizures), cardiac, pulmonary, metabolic, renal, hepatic, or gastrointestinal conditions
  • PR interval > 220 msec or QRS duration > 120 msec or QTcF interval > 450 msec obtained at screening visit or prior to the first dose of study drug
  • Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B virus surface antigen, or hepatitis C virus antibody at screening
  • Urinalysis positive for greater than trace blood, protein or glucose
  • History of drug or alcohol abuse within 6 months of screening
  • History of tobacco product use within 3 months prior to the study
  • Inability to comply with dietary restrictions during study participation
  • Blood donation or collection within 8 week prior to dosing
  • Positive pregnancy test

研究组 & 干预措施

Sequence 1

Experimental

Period 1: CTP-543 with meal Period 2: CTP-543 without meal

干预措施: CTP-543 (Drug)

Sequence 2

Experimental

Period 1: CTP-543 without meal Period 2: CTP-543 with meal

干预措施: CTP-543 (Drug)

结局指标

主要结局

Measurement of CTP-543 in plasma under fed and fasted conditions

时间窗: 48 hours

次要结局

未报告次要终点

研究者

发起方
Concert Pharmaceuticals
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验